A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
NCT ID: NCT05136677
Last Updated: 2026-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
102 participants
INTERVENTIONAL
2022-01-25
2025-11-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
NCT03195478
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
NCT04825873
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
NCT04153565
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
NCT06875076
Real World Study of MPM in China
NCT05042557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Arm B
Pemetrexed
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)
* Available tumor samples for centralized testing
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
* Measurable disease
Exclusion Criteria
* Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy
* Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0009
Beijing, Beijing Municipality, China
Local Institution - 0013
Harbin, Heilongjiang, China
Local Institution - 0006
Zhengzhou, Henan, China
Local Institution - 0005
Changsha, Hunan, China
Local Institution - 0023
Wuhan, Hunan, China
Local Institution - 0015
Yangzhou, Jiangsu, China
Local Institution - 0003
Changchun, Jilin, China
Local Institution - 0004
Shenyang, Liaoning, China
Local Institution - 0021
Shenyang, Liaoning, China
Local Institution - 0037
Jinan, Shandong, China
Local Institution - 0030
Qingdao, Shandong, China
Local Institution - 0001
Shanghai, Shanghai Municipality, China
Local Institution - 0033
Taiyuan, Shanxi, China
Local Institution - 0029
Chengdu, Sichuan, China
Local Institution - 0007
Tianjin, Tianjin Municipality, China
Local Institution - 0018
Tianjin, Tianjin Municipality, China
Local Institution - 0010
Kunming, Yunnan, China
Local Institution - 0014
Hangzhou, Zhejiang, China
Local Institution - 0020
Hangzhou, Zhejiang, China
Local Institution - 0012
Ningbo, Zhejiang, China
Local Institution - 0016
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1265-3913
Identifier Type: OTHER
Identifier Source: secondary_id
CA209-6DW
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.